guest ::
| Home > Publications database > Design of two-tail compounds with rotationally fixed benzenesulfonamide ring as inhibitors of carbonic anhydrases > print |
| Home > Publications database > Design of two-tail compounds with rotationally fixed benzenesulfonamide ring as inhibitors of carbonic anhydrases > print |
| 001 | 417251 | ||
| 005 | 20250729165318.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ejmech.2018.06.059 |2 doi |
| 024 | 7 | _ | |a 0009-4374 |2 ISSN |
| 024 | 7 | _ | |a 0223-5234 |2 ISSN |
| 024 | 7 | _ | |a 1768-3254 |2 ISSN |
| 024 | 7 | _ | |a pmid:30006175 |2 pmid |
| 024 | 7 | _ | |a WOS:000443663200006 |2 WOS |
| 024 | 7 | _ | |a altmetric:70381225 |2 altmetric |
| 024 | 7 | _ | |a openalex:W2811395998 |2 openalex |
| 037 | _ | _ | |a PUBDB-2018-05484 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Zakšauskas, Audrius |b 0 |
| 245 | _ | _ | |a Design of two-tail compounds with rotationally fixed benzenesulfonamide ring as inhibitors of carbonic anhydrases |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2018 |b Elsevier |
| 264 | _ | 1 | |3 print |2 Crossref |b Elsevier BV |c 2018-08-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1550261721_20859 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a © Elsevier Masson SAS. ; Final published version in progress; Post referee fulltext in progress; Embargo 12 months from publication |
| 520 | _ | _ | |a Rational design of compounds that would bind specific pockets of the target proteins is a difficult task in drug design. The 12 isoforms of catalytically active human carbonic anhydrases (CAs) have highly similar active sites that make it difficult to design inhibitors selective for one or several CA isoforms. A series of CA inhibitors based on 2-chloro/bromo-benzenesulfonamide that is largely fixed in the CA active site together with one or two tails yielded compounds that were synthesized and evaluated as inhibitors of CA isoforms. Introduction of a second tail had significant influence on the binding affinity and two-tailed compounds in most cases provided high affinity and selectivity for CA IX and CA XIV. The contacts between several compounds and CA amino acids were determined by X-ray crystallography. Together with the intrinsic enthalpy and entropy of binding they provided the structure-thermodynamics correlations for this series of compounds with the insight how to rationally build compounds with desired CA isoform as a target. |
| 536 | _ | _ | |a 899 - ohne Topic (POF3-899) |0 G:(DE-HGF)POF3-899 |c POF3-899 |f POF III |x 0 |
| 542 | _ | _ | |i 2018-08-01 |2 Crossref |u https://www.elsevier.com/tdm/userlicense/1.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 693 | _ | _ | |a PETRA III |f PETRA Beamline P13 |1 EXP:(DE-H253)PETRAIII-20150101 |0 EXP:(DE-H253)P-P13-20150101 |6 EXP:(DE-H253)P-P13-20150101 |x 0 |
| 693 | _ | _ | |a PETRA III |f PETRA Beamline P14 |1 EXP:(DE-H253)PETRAIII-20150101 |0 EXP:(DE-H253)P-P14-20150101 |6 EXP:(DE-H253)P-P14-20150101 |x 1 |
| 700 | 1 | _ | |a Čapkauskaitė, Edita |b 1 |
| 700 | 1 | _ | |a Jezepčikas, Linas |b 2 |
| 700 | 1 | _ | |a Linkuvienė, Vaida |b 3 |
| 700 | 1 | _ | |a Kišonaitė, Miglė |b 4 |
| 700 | 1 | _ | |a Smirnov, Alexey |b 5 |
| 700 | 1 | _ | |a Manakova, Elena |b 6 |
| 700 | 1 | _ | |a Grazulis, Saulius |0 P:(DE-H253)PIP1018629 |b 7 |
| 700 | 1 | _ | |a Matulis, Daumantas |0 0000-0002-6178-6276 |b 8 |e Corresponding author |
| 773 | 1 | 8 | |a 10.1016/j.ejmech.2018.06.059 |b : Elsevier BV, 2018-08-01 |p 61-78 |3 journal-article |2 Crossref |t European Journal of Medicinal Chemistry |v 156 |y 2018 |x 0223-5234 |
| 773 | _ | _ | |a 10.1016/j.ejmech.2018.06.059 |g Vol. 156, p. 61 - 78 |0 PERI:(DE-600)2005170-0 |p 61-78 |t European journal of medicinal chemistry |v 156 |y 2018 |x 0223-5234 |
| 909 | C | O | |p VDB |o oai:bib-pubdb1.desy.de:417251 |
| 910 | 1 | _ | |a Externes Institut |0 I:(DE-HGF)0 |k Extern |b 7 |6 P:(DE-H253)PIP1018629 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF3-890 |0 G:(DE-HGF)POF3-899 |2 G:(DE-HGF)POF3-800 |v ohne Topic |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2018 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J MED CHEM : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a No Fulltext |0 StatID:(DE-HGF)0551 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 920 | 1 | _ | |0 I:(DE-H253)EMBL-User-20120814 |k EMBL-User |l EMBL-User |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-H253)EMBL-User-20120814 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|